Abstract
We evaluated the known metabolic effects of aspirin in pregnant hypertensive patients. Eighty-seven pregnant women (12th–24th gestational week) were randomly allocated to low-dose aspirin or placebo treatment. Between the 24th–28th gestational week the following tests were performed: oral glucose tolerance test, venous blood pH and base excess, coagulation profile, platelet count, morning (8 a.m.) cortisol, creatinine clearance and serum uric acid. A significantly higher serum uric acid level was detected in the low-dose aspirin group (5.6±2.2 mg/dl) compared with the placebo group (4.7±1.2 mg/dl, p=0.048). No other significant difference was found for any of the other parameters tested. We conclude that low-dose aspirin treatment during the second half of pregnancy in hypertensive patients seems safe in terms of its effect on various maternal metabolic effects.
Get full access to this article
View all access options for this article.